A recent research has revealed that a cancer drug can help in reversing the transplant rejection.
Research team led by Steve Woodle of University of Cincinnati (U-C) found that drug bortezomib, used for treating cancer of plasma cells can treat rejection episodes caused by antibodies that target transplanted kidneys. It can also reverse rejection episodes that did not respond to standard therapies.
Woodle said that we found a body of literature demonstrating that bortezomib works well in suppressing transplant rejection in the laboratory.